Positive first half-year 2011 for Boehringer Ingelheim new growth from innovative medicines /Pradaxa approved in Europe
Ingelheim, Germany, 9 August 2011 – The
pharmaceutical company Boehringer Ingelheim has in the first half
of 2011 once again grown in local currency terms compared to the
previous year (+ 4 percent). Due to negative foreign exchange
effects, consolidation in euros shows growth of 2.6 percent, with
total net sales of EUR 6.4 billion against EUR 6.2 billion in the
first half of the previous year.
“We are pleased that, Boehringer Ingelheim has further developed positively in line with our expectations, particularly also through innovative medications that are ready for the market“, Professor Andreas Barner, Chairman of the Board of Managing Directors, underlined. “Our vision – Value through Innovation – thereby proves itself sustainably as the basis of our company."
Overall, Prescription Medicines’ net sales amounted to EUR 4.9 billion in the first half-year, broadly in line with the previous year’s level. After currency adjustment and taking into account structural business conditions (e. g. the expiry of exclusivity on medications in the USA and Germany), business grew by 10 percent in local currency terms, particularly in the USA, Japan and Canada. Some 60 percent of the increase in net sales was borne by the new launches of Pradaxa® (anticoagulant), Twynsta® (antihypertensive) and Tradjenta® (diabetes treatment). But established prescription medicines, such as Spiriva® and Micardis®, also showed market increases, with growth of 10 and 11 percent respectively.